ABSTRACT
Hormonal contraceptives are utilized by millions of women worldwide. However, it remains unclear if these powerful endocrine modulators may alter cognitive function. Habit formation involves the progression of instrumental learning as it goes from being a conscious goal-directed process to a cue-driven automatic habitual motor response. Dysregulated goal and/or habit is implicated in numerous psychopathologies, underscoring the relevance of examining the effect of hormonal contraceptives on goal-directed and habitual behavior. This study examined the effect of levonorgestrel (LNG), a widely used progestin-type contraceptive, on the development of habit in intact female rats. Rats were implanted with subcutaneous capsules that slowly released LNG over the course of the experiment or cholesterol-filled capsules. All female rats underwent operant training followed by reward devaluation to test for habit. One group of females was trained at a level that is sub-threshold to habit, while another group of females was trained to a level well over the habit threshold observed in intact females. The results reveal that all sub-threshold trained rats remained goal-directed irrespective of LGN treatment, suggesting LNG is not advancing habit formation in female rats at this level of reinforcement. However, in rats that were overtrained well above the threshold, cholesterol females showed habitual behavior, thus replicating a portion of our original studies. In contrast, LNG-treated habit-trained rats remained goal-directed, indicating that LNG impedes the development and/or expression of habit following this level of supra-threshold to habit training. Thus, LNG may offset habit formation by sustaining attentional or motivational processes during learning in intact female rats. These results may be clinically relevant to women using this type of hormonal contraceptive as well as in other progestin-based hormone therapies.
Subject(s)
Goals , Levonorgestrel , Humans , Rats , Female , Animals , Levonorgestrel/pharmacology , Progestins/pharmacology , Conditioning, Operant/physiology , Habits , Cholesterol/pharmacology , Contraceptive Agents/pharmacologyABSTRACT
Estradiol and progesterone potentiate and attenuate reward processes, respectively. Despite these well-characterized effects, there is minimal research on the effects of synthetic estrogens (e.g., ethinyl estradiol, or EE) and progestins (e.g., levonorgestrel, or LEVO) contained in clinically-utilized hormonal contraceptives. The present study characterized the separate effects of repeated exposure to EE or LEVO on responding maintained by a reinforcing visual stimulus. Forty ovary-intact female Sprague-Dawley rats received either sesame oil vehicle (n = 16), 0.18 µg/day EE (n = 16), or 0.6 µg/day LEVO (n = 8) subcutaneous injections 30-min before daily one-hour sessions. Rats' responding was maintained by a 30-sec visual stimulus on a Variable Ratio-3 schedule of reinforcement. The day after rats' last session, we determined rats estrous cycle phase via vaginal cytology before sacrifice and subsequently weighing each rat's uterus to further verify the contraceptive hormone manipulation. The visual stimulus functioned as a reinforcer, but neither EE nor LEVO enhanced visual stimulus maintained responding. Estrous cytology was consistent with normal cycling in vehicle rats and halting of normal cycling in EE and LEVO rats. EE increased uterine weights consistent with typical uterotrophic effects observed with estrogens, further confirming the physiological impacts of our EE and LEVO doses. In conclusion, a physiologically effective dose of neither EE nor LEVO did not alter the reinforcing efficacy of a visual stimulus reinforcer. Future research should characterize the effects of hormonal contraceptives on responding maintained by other reinforcer types to determine the generality of the present findings.
Subject(s)
Ethinyl Estradiol , Levonorgestrel , Rats, Sprague-Dawley , Animals , Female , Ethinyl Estradiol/pharmacology , Ethinyl Estradiol/administration & dosage , Levonorgestrel/pharmacology , Levonorgestrel/administration & dosage , Rats , Reinforcement, Psychology , Photic Stimulation/methods , Ovary/drug effects , Estrous Cycle/drug effectsABSTRACT
Overview of: Li RHW, Lo SST, Gemzell-Danielsson K, et al. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial [correction appears in Lancet 2023;402:850]. Lancet 2023;402:851-8.
Subject(s)
Contraception, Postcoital , Humans , Levonorgestrel/therapeutic use , Levonorgestrel/pharmacology , Piroxicam , Double-Blind MethodABSTRACT
Despite the evidence of altered emotion processing in oral contraceptive (OC) users, the impact of hormonal intrauterine devices (IUD) on emotional processing remains unexplored. Our study aimed to investigate how behavioural performance and event-related potentials (ERPs) linked with emotion reactivity and its regulation are associated with hormonal profiles of women using different types of hormonal contraception and naturally cycling women. Women using OCs (n = 25), hormonal IUDs (n = 33), and naturally cycling women in their early follicular (NCF, n = 33) or mid-luteal (NCL, n = 28) phase of the menstrual cycle were instructed to view emotional pictures (neutral, low and high negativity) and use cognitive reappraisal to up- or down-regulate negative emotions, while their electroencephalogram was recorded. Participants rated perceived negativity after each picture and their emotional arousal throughout the task. Saliva samples were collected to assess levels of 17ß-estradiol, progesterone, and testosterone. As expected, emotional arousal increased throughout the task and correlated positively with perceived negativity. Perceived negativity and the amplitudes of the middle (N2/P3) and later (LPP) latency ERP components increased with increasing stimuli negativity. Emotion regulation modulated perceived negativity and the amplitudes of very late ERP components (parietal and frontal LPP). Moreover, IUD-users showed a higher negative amplitude of the frontal N2 in comparison to all three other groups, with the most consistent differences during up-regulation. Finally, testosterone correlated positively with the N2 peak in IUD-users and NCL women. Overall, our findings suggest that IUD-use and testosterone might be related to altered preconscious processing during the emotion regulation task requiring attention to the stimulus. The study underscores the need for additional research into how different hormonal contraceptives are linked to socio-emotional functioning.
Subject(s)
Intrauterine Devices , Levonorgestrel , Female , Humans , Levonorgestrel/pharmacology , Menstrual Cycle/physiology , Progesterone , TestosteroneABSTRACT
Incidence of endometrial cancer (EC) is rising in the developed world. The current standard of care, hysterectomy, is often infeasible for younger patients and those with high body mass index. There are limited non-surgical treatment options and a lack of biologically relevant research models to investigate novel alternatives to surgery for EC. The aim of the present study was to develop a long-term, patient-derived explant (PDE) model of early-stage EC and demonstrate its use for investigating predictive biomarkers for a current non-surgical treatment option, the levonorgestrel intra-uterine system (LNG-IUS). Fresh tumour specimens were obtained from patients with early-stage endometrioid EC. Tumours were cut into explants, cultured on media-soaked gelatin sponges for up to 21 days and treated with LNG. Formalin-fixed, paraffin embedded (FFPE) blocks were generated for each explant after 21 days in culture. Tumour architecture and integrity were assessed by haematoxylin and eosin (H&E) and immunohistochemistry (IHC). IHC was additionally performed for the expression of five candidate biomarkers of LNG resistance. The developed ex vivo PDE model is capable of culturing explants from early-stage EC tumours long-term (21 Days). This model can complement existing models and may serve as a tool to validate results obtained in higher-throughput in vitro studies. Our study provides the foundation to validate the extent to which EC PDEs reflect patient response in future research.
Subject(s)
Endometrial Neoplasms , Intrauterine Devices, Medicated , Female , Humans , Levonorgestrel/pharmacology , Endometrial Neoplasms/pathology , Hysterectomy , BiomarkersABSTRACT
Introduction: To characterize the influence of female-specific hormones on women's thyroid function, the study investigated the influence of extra progestin from oral contraceptives on inducing thyroid dysfunction. Methods: Sixty female Wistar rats were divided into six groups based on levonorgestrel or desogestrel administration as the main active agents: control, low (0.0039 mg*20-fold), medium (0.0039 mg*100-fold), high (0.0318 mg*100-fold) levonorgestrel (pure product); and low (0.0083 mg*20-fold) and high (0.0083 mg*100-fold) desogestrel (pure product). Progestin was administered by gavage every 4 days for 1 month. Statistical analysis was performed using one-way analysis of variance and the Kruskal-Wallis test. Results: Following levonorgestrel gavage, serum free T4 and thyroidstimulating hormone levels were significantly lower in the experimental group than that in the control group (p=0.013 and 0.043). After desogestrel gavage, the serum free T4 and free T3 levels were lower in the experimental group than that in the control group (p=0.019 and 0.030). Thyroid hormone antibody concentrations were lower in rats administered levonorgestrel and desogestrel than that in control rats. Moreover, exposure to progestin upregulated the expression of the thyroid-stimulating hormone receptor and sodium iodide symporter in thyroid. Discussion: Progestin stimulation enhanced the proliferation of follicular epithelial cells in rat thyroid tissues. Progestin exposure could cause thyroid dysfunction by upregulating the transcription of thyroid-stimulating hormone receptor and sodium iodide symporter in thyroid, thus inducing pathomorphological changes in rats' thyroid.
Subject(s)
Desogestrel , Levonorgestrel , Progestins , Rats, Wistar , Thyroid Gland , Animals , Female , Rats , Progestins/pharmacology , Progestins/adverse effects , Thyroid Gland/drug effects , Thyroid Gland/metabolism , Levonorgestrel/pharmacology , Desogestrel/administration & dosage , Desogestrel/pharmacology , Thyroxine/blood , Thyroid Hormones/blood , Thyroid Function TestsABSTRACT
PURPOSE: Midostaurin, approved for treating FLT-3-mutated acute myeloid leukemia and advanced systemic mastocytosis, is metabolized by cytochrome P450 (CYP) 3A4 to two major metabolites, and may inhibit and/or induce CYP3A, CYP2B6, and CYP2C8. Two studies investigated the impact of midostaurin on CYP substrate drugs and oral contraceptives in healthy participants. METHODS: Using sentinel dosing for participants' safety, the effects of midostaurin at steady state following 25-day (Study 1) or 24-day (Study 2) dosing with 50 mg twice daily were evaluated on CYP substrates, midazolam (CYP3A4), bupropion (CYP2B6), and pioglitazone (CYP2C8) in Study 1; and monophasic oral contraceptives (containing ethinylestradiol [EES] and levonorgestrel [LVG]) in Study 2. RESULTS: In Study 1, midostaurin resulted in a 10% increase in midazolam peak plasma concentrations (Cmax), and 3-4% decrease in total exposures (AUC). Bupropion showed a 55% decrease in Cmax and 48-49% decrease in AUCs. Pioglitazone showed a 10% decrease in Cmax and 6% decrease in AUC. In Study 2, midostaurin resulted in a 26% increase in Cmax and 7-10% increase in AUC of EES; and a 19% increase in Cmax and 29-42% increase in AUC of LVG. Midostaurin 50 mg twice daily for 28 days ensured that steady-state concentrations of midostaurin and the active metabolites were achieved by the time of CYP substrate drugs or oral contraceptive dosing. No safety concerns were reported. CONCLUSION: Midostaurin neither inhibits nor induces CYP3A4 and CYP2C8, and weakly induces CYP2B6. Midostaurin at steady state has no clinically relevant PK interaction on hormonal contraceptives. All treatments were well tolerated.
Subject(s)
Bupropion , Cytochrome P-450 CYP2B6 , Cytochrome P-450 CYP2C8 , Cytochrome P-450 CYP3A , Drug Interactions , Midazolam , Staurosporine , Humans , Area Under Curve , Bupropion/pharmacokinetics , Bupropion/administration & dosage , Contraceptives, Oral/administration & dosage , Contraceptives, Oral/pharmacology , Contraceptives, Oral/pharmacokinetics , Cytochrome P-450 CYP2B6/metabolism , Cytochrome P-450 CYP2B6/genetics , Cytochrome P-450 CYP2C8/metabolism , Cytochrome P-450 CYP3A/metabolism , Drug Combinations , Ethinyl Estradiol/pharmacokinetics , Ethinyl Estradiol/administration & dosage , Ethinyl Estradiol/pharmacology , Healthy Volunteers , Levonorgestrel/pharmacokinetics , Levonorgestrel/administration & dosage , Levonorgestrel/pharmacology , Midazolam/pharmacokinetics , Midazolam/administration & dosage , Pioglitazone/pharmacology , Pioglitazone/administration & dosage , Pioglitazone/pharmacokinetics , Staurosporine/analogs & derivatives , Staurosporine/pharmacology , Staurosporine/pharmacokinetics , Staurosporine/administration & dosage , Male , Female , Adolescent , Young Adult , Adult , Middle AgedABSTRACT
Adolescent girls bear a disproportionate burden of both the HIV epidemic and unintended pregnancies; yet important questions remain unanswered regarding the effects of hormonal contraceptives on the vaginal immune microenvironment, which can impact HIV susceptibility in this group. Multiple studies report genital immune alterations associated with the progestin-based contraceptive Depot medroxyprogesterone acetate (DMPA) in adult women, but there is little available data in adolescents. The objective of this longitudinal cohort study was to evaluate the effects of short-term use of three progestin-based contraceptives, levonorgestrel intrauterine device (LNG-IUD), subdermal etonogestrel (ETNG), and injectable DMPA, on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls. Fifty-nine sexually active, HIV-uninfected girls aged 15-19, were recruited from the Washington DC metro area and self-selected into Control (condoms only), combined oral contraceptive pills, LNG-IUD, ETNG and DMPA groups. Vaginal swabs were collected at baseline prior to contraceptive use and at 3-month follow-up visit. Vaginal secretions were tested for pro-inflammatory (IL-1α, IL-1ß, TNF-α, IL-6, IL-8, MIP-3α, IP-10, RANTES, MIP-1α, MIP-1ß) and anti-inflammatory/anti-HIV (Serpin-A1, Elafin, Beta-Defensin-2, SLPI) immune biomarkers using ELISA and for anti-HIV activity using TZM-bl assay. Vaginal microbiome was evaluated using 16S rRNA gene sequencing. Data were analyzed using SAS Version 9. Among the 34 participants who completed both visits, no significant changes in median biomarker concentrations, HIV inhibition and microbiome composition were observed between baseline and follow-up visits for any of the contraceptive groups. IL-8 (p<0.01), MIP-3α (0.02), Elafin (p = 0.03) and RANTES (p<0.01) differed significantly by race whereas IL-6 was significantly different by age (p = 0.03). We conclude that 3-month use of LNG-IUD, ETNG and DMPA have minimal effects on adolescent vaginal immune microenvironment, and therefore unlikely to impact HIV risk. Future studies with larger sample size and longer follow-up are recommended to continue to evaluate effects of contraceptives on the lower genital tract immunity and susceptibility to sexually transmitted infections.
Subject(s)
Biomarkers , Desogestrel , HIV Infections , Levonorgestrel , Medroxyprogesterone Acetate , Microbiota , Vagina , Humans , Female , Adolescent , Vagina/microbiology , Vagina/immunology , Vagina/drug effects , HIV Infections/immunology , Microbiota/drug effects , Biomarkers/metabolism , Medroxyprogesterone Acetate/administration & dosage , Medroxyprogesterone Acetate/adverse effects , Medroxyprogesterone Acetate/pharmacology , Young Adult , Levonorgestrel/pharmacology , Levonorgestrel/administration & dosage , Desogestrel/administration & dosage , Contraceptive Agents, Female/administration & dosage , Contraceptive Agents, Female/pharmacology , Longitudinal Studies , Progestins/pharmacology , Progestins/administration & dosage , ElafinABSTRACT
Abstract Background: Levonorgestrel (LNG) is a progesterone receptor agonist used in both regular and emergency hormonal contraception; however, its effects on the endometrium as a contraceptive remain widely unknown and under public debate. Objective: To analyze the effects of LNG or mifepristone (MFP), a progesterone receptor antagonist and also known as RU-486, administered at the time of follicle rupture (FR) on endometrial transcriptome during the receptive period of the menstrual cycle. Methods: Ten volunteers ovulatory women were studied during two menstrual cycles, a control cycle and a consecutively treated cycle; in this last case, women were randomly allocated to two groups of 5 women each, receiving one dose of LNG (1.5 mg) or MFP (50 mg) the day of the FR by ultrasound. Endometrial biopsies were taken 6 days after drug administration and prepared for microarray analysis. Results: Genomic functional analysis in the LNG-treated group showed as activated the bio-functions embryo implantation and decidualization, while these bio-functions in the T-MFP group were predicted as inhibited. Conclusions: The administration of LNG as a hormonal emergency contraceptive resulted in an endometrial gene expression profile associated with receptivity. These results agree on the concept that LNG does not affect endometrial receptivity and/or embryo implantation when used as an emergency contraceptive.
Subject(s)
Humans , Female , Adult , Young Adult , Embryo Implantation/drug effects , Mifepristone/pharmacology , Levonorgestrel/pharmacology , Contraceptives, Postcoital, Hormonal/pharmacology , Endometrium , Transcriptome/drug effects , Ovulation , Time Factors , Mifepristone/administration & dosage , Levonorgestrel/administration & dosage , Contraceptives, Postcoital, Hormonal/administration & dosageABSTRACT
Os índices de prenhez após inseminação artificial em felídeos selvagens não são satisfatórios devido ao variável ambiente endócrino após a estimulação com gonadotropinas. O objetivo deste estudo consistiuem aumentar a taxa de sucesso em programas de inseminação artificial em gatas domésticas (animal modelo). As fêmeas (n=9) foram divididas em três grupos, cada um com três animais, sendo: 1) controle(C), somente 200 UI eCG/ 100 UI hCG ; 2) levonorgestrel oral (L)(0,075 mg) durante 37 dias + eCG/hCG; 3) etonogestrel (E), implante subdérmico durante 37 dias + eCG/hCG. Foram submetidas ao exame laparoscópico 29-39 horas após a administração de hCG para verificação da resposta ovariana e realização de esfregaço vaginal para monitoração da fase do ciclo estral. Foram coletadas amostras de fezes 60 dias antes e 60 dias após o tratamento com gonadotropinas para dosagem hormonal de estrógenos. Os resultados foram avaliados através do Teste ANOVA. Os níveis de significância mostraram que o Grupo E, em contraste com o Grupo C e o Grupo L, apresentou inibição satisfatória das concentrações de estrógenos durante a sua utilização. O grupo L não apresentou inibição ovariana durante o tratamento e diferença significativa em relação ao Grupo C. No exame laparoscópico todas as fêmeas dos grupos C, L e E apresentaram folículos e 77% das fêmeas apresentaram corpo lúteo. Também apresentaram células epiteliais superficiais anucleadas e nucleadas características de estro. Concluiu-se que a utilização de implantes de etonogestrel em gatas domésticas mostrou-se eficaz, possibilitando asua utilização prévia aos programas de inseminação artificial, aspiração folicular e também para a contracepção.
Reproductive success in endangered captive small felids species is veryl ow. Due to great variability in endocrine environment post gonadotropin treatment, after artificial insemination pregnancy rates are very low. Nowadays, ovarian activity controll improves the AI success in many species. In this study, new protocols were compared to improve the fertilization rates in artificial insemination programs in domestic cat. Female domestic cats were divided in three treatments: 1) control (eCG/hCG); 2) levonorgestrel (0.075 mg) orally during 37days + eCG/hCG; 3) etonogestrel subdermal implant during 37days + eCG/hCG: Laparoscopies were done 29-39 hours post hCG treatment to verify ovarian activity. Vaginal swabs were collected at laparoscopic procedures. Fecal samples were colected 60 days before, during and 60 days after the gonadotropin treatment for estradiol assay. Means comparisons were done by ANOVA test. Results demonstrated that etonogestrel (implant) and not oral levonorgestrel successfully suppressed ovarian activity. The levonorgestrel group didnot show ovarian inactivity during the administration, presenting oestradiol peaks and without significative diference comparing to control group. All females presented anuclear and nuclear superficial vaginal epithelial cells at laparoscopies. In conclusion, the etonogestrel implant used in the domestic cat was efficient and can be used previous to gonadotropin protocol in artificial insemination programs, follicular aspiration and contraception
Subject(s)
Animals , Female , Contraceptives, Oral, Synthetic/pharmacology , Fertilization/physiology , Cats/physiology , Ovulation Induction/veterinary , Insemination, Artificial/veterinary , Ovary/physiology , Analysis of Variance , Contraception/methods , Desogestrel/pharmacology , Fertilization , Gonadotropins/pharmacology , Insemination, Artificial/standards , Levonorgestrel/pharmacologyABSTRACT
A pesar de lo extendido del uso de la anticoncepción de emergencia (AE) con levonorgestrel (LNG) en el mundo, el mecanismo de acción continúa siendo discutido, lo que ha sido aprovechado para que grupos confesionales aaquen su uso, argumentando que la misma es abortiva. Actualmente, dos comprimido de LNG de 0,75 mg hasta 5 días posteriores al coito no protegido, ha sido recomendada y mostrada como eficaz para AE. El mecanismo de acción probablemente depende del momento de la toma en relación al día del ciclo menstrual. Cuando el LNG para AE es administrado antes del período ovulatorio, el mismo inhibe la ovulación en algunas mujeres y afecta el endometrio. Sin embargo la administración de LNG antes de la ruptura folicular no mostró tener influencia sobre la expresión de glicodelina-A en biopsias de endometrio tomadas 24 o 48 horas después de la toma de las píldoras de LNG. Los resultados de los estudios no apoyan la idea de que el LNG como AE causaría un efecto anti-implantatorio. Fue especulado que el LNG podría actuar sobre los espermatozoides. En estudios muy antiguos de la Argentina fue observado que la administración de 0,4 mg de LNG dado 3-10 horas post coito reducía el número de espermatozoides recuperados de la cavidad uterina, causaba alcalinización del fluido intrauterino, inmovilizaba los espermatozoides y aumentaba la viscosidad del moco cervical. Esto llevó a sugerir que la migración espermática a los lugares de fertilización podría esar comprometida después de la ingesta de LNG como AE. Sin embargo, nosotros hemos trabajado sobre esta hipótesis, pero no observamos efectos sobre reacción acrosomal después de la exposición in vitro al LNG de espermatozoides capacitados...
Subject(s)
Female , Humans , Levonorgestrel/administration & dosage , Levonorgestrel/pharmacology , Levonorgestrel/therapeutic use , Contraceptive Agents, Female/administration & dosage , Contraceptive Agents, Female/pharmacokinetics , Contraceptive Agents, Female/therapeutic use , Contraceptives, Postcoital, Hormonal/administration & dosage , Contraceptives, Postcoital, Hormonal/pharmacokinetics , Contraceptives, Postcoital, Hormonal/therapeutic use , Contraceptives, Postcoital, Synthetic/administration & dosage , Contraceptives, Postcoital, Synthetic/pharmacokinetics , Contraceptives, Postcoital, Synthetic/therapeutic useABSTRACT
En esta revisión se actualiza el mecanismo de acción del levonorgestrel (LNG) usado en anticoncepción de emergencia. El análisis crítico de la estimación de la eficacia anticonceptiva del LNG indica que su tasa de falla es más alta que la publicada. El LNG aumenta la viscosidad del moco cervical impidiendo que los espermatozoides del reservorio cervical vayan a renovar la población espermática en el sitio de fecundación. Diversos autores han documentado que LNG suprime el pico preovulatorio de gonadotrofinas e interfiere con el proceso ovulatorio en la mujer y en modelos animales. Administrado después de la ovulación en rata, en la mona Cebus apella y en la mujer, no interfiere con la implantación del embrión. Se concluye que LNG previene el embarazo solamente cuando se administra en un momento del ciclo menstrual en el cual puede impedir la fecundación y que el método falla cuando la administración es más tardía.
This review updates the mechanism of action of levonorgestrel (LNG) used for emergency contraception. A critical analysis of estimates of the contraceptive efficacy of LNG indicates that its failure rate is higher than previously reported. Under the effect of LNG, cervical mucus turns highly viscous and hinders the exit of sperm from the cervical reservoir needed to renew the sperm population at the site of fertilization. Several authors have documented that LNG suppresses the preovulatory surge of gonadotropins and interferes with the ovulatory process in women and in animal models. Administered after ovulation in the rat, in the Cebus apella monkey and women, LNG does not interfere with embryo implantation. In conclusion, LNG prevents pregnancy only when it is administered at a time of the menstrual cycle in which it can impede fertilization and the method fails when it is given at later stages of the cycle.
Subject(s)
Humans , Female , Contraceptives, Postcoital/pharmacology , Levonorgestrel/pharmacology , OvulationABSTRACT
OBJETIVO: Determinar a variação de peso corpóreo em mulheres usuárias de sistema intra-uterino liberador de 20 mg/dia de levonorgestrel (SIU-LNG, Mirena®) e compará-la com a variação de peso de usuárias de dispositivo intra-uterino T cobre 380A (DIU Tcu) e usuárias de acetato de medroxiprogesterona de depósito (AMP-D) ao longo de cinco anos. MÉTODOS: Foram analisadas 163 mulheres usuárias de SIU-LNG que tiveram a inserção do mesmo em 1998 durante a admissão para o estudo. Cada mulher foi pareada por peso (± 1kg) e por idade (± 1 ano) no início do estudo, com as usuárias de DIU Tcu e AMP-D. Todas as mulheres foram seguidas por até cinco anos. Nesse período foram medidos seus pesos e calculados os índices de massa corpórea (IMC). RESULTADOS: A média de idade das usuárias de SIU-LNG foi 27±6,7 anos, enquanto que das usuárias de DIU Tcu foi 28±6,6 anos e das usuárias de AMP-D foi de 26,9±6,5 anos. O peso inicial era 62,9 ± 0,8 kg, 62,8 ± 0,8 kg e 62,5 ± 0,9 kg para as usuárias de SIU-LNG, DIU Tcu e AMP-D, respectivamente. O IMC no início do estudo era 25 (±0,3), 26,4 (±0,3) e 25,5 (±0,4) para as usuárias de SIU-LNG, DIU Tcu e AMP-D, respectivamente. Foi observado um aumento de peso de 3,1 kg, 4,9 kg e 8,2 kg para as usuárias de SIU-LNG, DIU Tcu e AMP-D, respectivamente, ao final do quinto ano (p=0,009). O IMC também apresentou um aumento em todos os grupos (IMC final de 26,3 ± 0,7, 28,5 ± 0,8 e 28,7 ± 1,3 para as usuárias de SIU-LNG, DIU Tcu e AMP-D, respectivamente). A análise multivariada mostrou que o uso de AMP-D e seu tempo de uso foram significativos em relação ao ganho de peso. CONCLUSAO: O uso de SIU-LNG não mostrou aumento significativo no ganho de peso ao longo dos cinco anos, bem como diferença na variação de peso quando comparado com o uso de DIU Tcu.
Subject(s)
Humans , Female , Adult , Contraceptive Agents, Female/administration & dosage , Intrauterine Devices, Medicated , Levonorgestrel/administration & dosage , /administration & dosage , Weight Gain/drug effects , Body Mass Index , Brazil , Contraceptive Agents, Female/pharmacology , Follow-Up Studies , Intrauterine Devices, Copper , Levonorgestrel/pharmacology , /pharmacology , Multivariate AnalysisABSTRACT
En esta revisión se actualiza el mecanismo de acción del levonorgestrel (LNG) usado en anticoncepción de emergencia. El análisis crítico de la estimación de la eficacia anticonceptiva del LNG indica que su tasa de falla es más alta que la publicada. El LNG aumenta la viscosidad del moco cervical impidiendo que los espermatozoides del reservorio cervical vayan a renovar la población espermática en el sitio de fecundación. Diversos autores han documentado que LNG suprime el pico preovulatorio de gonadotrofinas e interfiere con el proceso ovulatorio en la mujer y en modelos animales. Administrado después de la fecundación en rata y Cebus apella, no interfiere con la implantación del embrión. Se concluye que LNG previene el embarazo solamente cuando se administra en un momento del ciclo menstrual en el cual puede impedir la fecundación y que el método falla cuando la administración es más tardía.
Subject(s)
Humans , Female , Levonorgestrel/pharmacology , Ovulation , Sperm Transport , Contraception , Levonorgestrel/administration & dosageSubject(s)
Humans , Contraception, Postcoital/standards , Fertilization , Levonorgestrel/pharmacology , Public Opinion , Chile , EthicsABSTRACT
O objetivo da pesquisa foi conhecer a experiência e a opiniäo de um grupo de mulheres brasileiras que aceitaram experimentar o sistema anticoncepcional Norplant. Foram estudadas 280 mulheres, selecionadas em três clínicas de planejamento familiar em Campinas, Curitiba e Fortaleza. Houve poucas diferenças significativas entre as clínicas. A equimose foi a moléstia mais freqüentemente relacionada com a inserçäo (60%), e a coceira foi o sintoma local mais comumente mencionado (40%) durante o uso. A percentagem de mulheres que disseram que as cólicas menstruais, corrimento, dor de cabeça e nervosismo tinham diminuido com o uso do método foi maior do que a das que relataram aumento. Mais da metade das mulheres estudadas estiveram em amenorréia durante dois ou mais meses, ou menstruaram, sangraram e/ou mancharam durante dez ou mais dias em um mês. A grande maioria das usuárias (77,2%) considerou "boa ou "muito boa" sua experiência com o Norplant e 80,6% disse tê-lo recomendado a outra mulher
Subject(s)
Humans , Female , Levonorgestrel , Patient Acceptance of Health Care , Drug Evaluation , Drug Implants , Interviews as Topic , Levonorgestrel/pharmacologyABSTRACT
En su boletín N°51 de 1999, el UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, principal iniciativa de la OMS en el campo de salud reproductiva, reconoce que a la fecha no existe información sobre el modo de acción del levonorgestrel en dosis de dos tabletas de 0.75 mg dadas con un intervalo de 12 horas, y que se están llevando a efecto investigaciones sobre el efecto de esta régimen sobre los distintos eventos que llevan a la fertilización y al establecimiento del embarazo. Croxatto (2001), en la revisión más reciente sobre el tema disponible en la literatura, concluye tambien que Existen pocos estudios diseñados para buscar el mecanismo de acción del levonorgestrel en la contracepción de emergencia y su modo de acción preciso sigue siendo desconocido.